Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Physicians treating adolescents should take a complete sexual history, including sexual orientation and practices, to determine whether their patients are homosexually active. Lesbians are at very low risk for sexually transmitted diseases, but they do have other health concerns. Four general groups of conditions may be encountered in homosexually active men: classical sexually transmitted diseases (gonorrhea, infections with Chlamydia trachomatis, syphilis, herpes simplex infections, genital warts, pubic lice, scabies); enteric diseases (infections with Shigella species, Campylobacter jejuni, Entamoeba histolytica, Giardia lamblia, hepatitis A, hepatitis B, hepatitis non-A, non-B, and cytomegalovirus); trauma (fecal incontinence, hemorrhoids, anal fissure, foreign bodies, rectosigmoid tears, allergic proctitis, penile edema, chemical sinusitis, inhaled nitrite burns, and sexual assault of the male patient); and the acquired immunodeficiency syndrome (AIDS). Clinicians can assist homosexual teenagers by understanding their special health needs, by counseling them about safe sexual practices, and by accepting their relationships nonjudgmentally.
 ...
PMID:Medical problems of the homosexual adolescent. 383 19

Reports of cases of primary and secondary syphilis are increasing in the United States, particularly in urban areas and among homosexual men. While primary syphilis poses little diagnostic difficulty, many physicians are unfamiliar with the multisystem nature of secondary lues. Patients who have secondary syphilis commonly present with systemic signs, skin rash, mucous membrane lesions and generalized adenopathy. Less commonly, secondary syphilis may occur as acute meningitis, sensorineural hearing loss, iritis, anterior uveitis, optic neuritis, Bell's palsy, gastropathy, proctitis, hepatitis, pulmonary infiltration, nephrotic syndrome, glomerulonephritis, periostitis, tenosynovitis and polyarthritis. The diagnosis of secondary syphilis is easily confirmed. Its various manifestations are readily treated with penicillin and, if treated early, are entirely reversible. Two recent cases of secondary syphilis, one presenting as nephrotic syndrome and one as chorioretinitis and ptosis, illustrate the usual and unusual features of this common infection.
 ...
PMID:Secondary syphilis: uncommon manifestations of a common disease. 670 90

Large bowel disease detected clinically by rectal prolapse was studied in 64 immunodeficient mice (37 athymic NCr-nu/nu, 12 BALB/c AnNCr-nu/nu, 9 C57BL/6NCr-nu/nu, and 6 C.B17/Icr-scid/NCr) naturally infected with Helicobacter hepaticus. Rectal prolapse was found in approximately 5% of immunodeficient mice maintained in a research facility over a period of 3.5 years. All mice had various degrees of chronic proliferative typhlitis, colitis, and proctitis, usually without concomitant hepatitis. Some mice had severe proliferative proctitis with cystic hyperplasia. Histologic study of the large bowel of 48 athymic NCr-nu/nu mice without H. hepaticus infection and housed in another clean facility revealed only 12% of the mice with minimal-to-mild large bowel inflammation. Helicobacter hepaticus infection is associated with large bowel disease in immunodeficient mice but is not seen in H. hepaticus-infected immunocompetent mice. This new pathogenic bacterial infection should be considered as another potential cause or co-factor for rectal prolapse and large bowel disease in mice.
 ...
PMID:Inflammatory large bowel disease in immunodeficient mice naturally infected with Helicobacter hepaticus. 869 13

WF 10 [TCDO, Oxoferin, Immunokine, Macrokine] is a 1:10 dilution of tetrachlorodecaoxide formulated for IV delivery. It was developed by Oxo Chemie in Switzerland as an adjunctive therapy to combination antiretroviral and opportunistic infection prophylaxis regimens in AIDS patients. WF 10 specifically targets macrophages. Oxo Chemie has worldwide patent rights to WF 10 and Dimethaid Research has an exclusive licence for marketing and distribution in Canada. In May 2002, Oxo Chemie was acquired by Dimethaid Research. Oxo completed a trial in 72 cervical cancer patients undergoing radiation therapy in 1989. Results from this trial demonstrated complete remission in 75% of patients receiving WF 10. A follow-up placebo controlled trial in 1996 produced similar results. WF 10 has received regulatory approval in Thailand for postradiation cystitis following a trial completed in 1998 in 20 patients following radiation treatment for cervical carcinoma. This authorisation also allows limited availability of WF 10 at the physician's request in Germany. WF 10 is also available under Health Canada's Special Access Program. Oxo Chemie has completed a controlled randomised, crossover study in France in 1991 that examined the effects of 103 patients with acute radiation dermatitis and radiation- or chemotherapy-induced mucositis. Results demonstrated that WF 10 significantly improved lesions and accelerated recovery without side effects. Topical tetrachlorodecaoxide in a less concentrated formulation (1:55) is marketed in many countries as Oxoferin for wound healing. WF 10 is approved for use in Thailand under the name IMMUNOKINE in patients with postradiation chronic inflammatory disease including cystitis, proctitis and mucositis. In July 2003, the European examiners informed Oxo Chemie that they intend to grant the company additional patents to the technology platform that supports WF 10, extending the European protection granted in 1992 to cover a much broader range of diseases. The patents will be granted in Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, the Netherlands, Portugal, Spain, Sweden, Switzerland and the UK. Patent claims cover potential treatment for autoimmune disease, organ transplant or graft rejection, lymphoma and inflammation manifested as hepatitis or chronic obstructive pulmonary disease.
 ...
PMID:WF 10: Macrokine, TCDO, tetrachlorodecaoxide. 1523 Jun 35

We report the first known case of syphilis with simultaneous manifestations of proctitis, gastritis, and hepatitis. The diagnosis of syphilitic proctitis and gastritis was established by the demonstration of spirochetes with anti-Treponema pallidum antibody staining in biopsy specimens. Unusual manifestations of secondary syphilis completely resolved after 4 weeks of antibiotic therapy.
 ...
PMID:Case of secondary syphilis presenting with unusual complications: syphilitic proctitis, gastritis, and hepatitis. 2199 11

Localised prostate cancer, confined to the prostate gland, occurs mainly in men over 65 years of age. The principal management options are watchful waiting, prostatectomy and radiation therapy. Which of these options has the best harm-benefit balance for patients with localised prostate cancer? To answer this question, we conducted a review of the literature using the standard Prescrire methodology. The natural history of localised prostate cancer depends on the extent and histologic grade of the tumour, and pretreatment PSA level. Without immediate treatment, the risk of death from prostate cancer that only one involves one lobe, a Gleason histological score of 7 or less, and a PSA level of 20 ng/ml or lower is less than 0.5% per year. The risk is about 4% per year in patients with larger tumours, poorly differentiated cancer cells (Gleason score above 7), or an elevated PSA level. Most data on radical prostatectomy come from a randomised trial versus watchful waiting in 695 men with localised cancer. Prostatectomy reduced all-cause mortality after a median followup of about 13 years (46% versus 53% without treatment), but this benefit was only seen in patients younger than 65 years at diagnosis. After 4 years of follow-up, prostatectomy was associated with erectile dysfunction in approximately 40% of patients and with incontinence in about 25% of patients. External beam radiation therapy reduced overall mortality to a lesser degree than prostatectomy, but the level of evidence is lower for this modality. Brachytherapy (implantation of a radioactive isotope in the prostate) has not been compared directly with other treatments. Transient radiation proctitis is common after external beam radiation therapy. About 15% of patients treated with external beam radiation therapy and 10% of patients treated with brachytherapy experience long-term intestinal disorders. About half of patients treated with external beam radiation therapy and the majority of patients treated with brachytherapy have transient symptoms of radiation cystitis. In the long term, about 5% of patients treated with radiation therapy have urinary incontinence, versus 12% to 25% of surgical patients. In the long term, about 75% of surgical patients experience erectile dysfunction, compared to about 60% of patients treated with external beam radiation therapy and about 50% of patients who opt for watchful waiting. Brachytherapy appears to cause less erectile dysfunction than external beam radiation therapy. In patients treated with external beam radiation therapy, the addition of hormone therapy for 4 to 6 months reduced all-cause mortality in two randomised trials but caused gynaecomastia, more erectile dysfunction, hot flashes, and hepatitis. Hormone therapy has an unfavourable harm-benefit balance when used alone to treat localised prostate cancer. Further studies of cryotherapy and high-intensity focused ultrasound therapy are needed to determine their respective benefits and harms. In practice, watchful waiting is the most reasonable option for men with low-risk localised prostate cancer and a life expectancy of less than 10 years. In men with low- or intermediate-risk localised prostate cancer and a life expectancy of more than 10 years, there is insufficient data available in early 2012 to show which of the following options is preferable: watchful waiting, radical prostatectomy, external beam radiation therapy, or brachytherapy. Patients should be informed of the risks associated with each of these options and should be actively involved in the choice of treatment. Treatment is often warranted for patients with high-risk localised prostate cancer.The main options are either radical prostatectomy or external beam radiation therapy combined with hormone therapy.
 ...
PMID:Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow. 2318 49